Effect of neuromimetics upon the release of atrial natriuretic peptide granules: are multiple pathways involved in secretion?
The release of atrial natriuretic peptide (ANP) in response to the application of neurohumoral agonists (neuromimetics) is directly demonstrated and quantified at the cellular level, using an ultrastructural assay developed to quantify secretion. The assay uses an in situ tannic acid perfusion technique to arrest the exocytosis of atrial secretory granules in the anesthetized rat. The animal is perfused with the neuromimetic, and secretory granules, which retain the capacity to undergo exocytosis throughout the subsequent 30 min tannic acid perfusion, accumulate at the cell surface in a state of fusion with the plasma membrane. Quantification of arrested granules thus provides a measure of the rate of granule release and allows the responses to different agents to be assessed. The actions of three different agents were investigated: isoproterenol, phenylephrine, and acetylcholine. In previously published studies, investigations of the actions of these agents on ANP release has produced unclear and sometimes contradictory results. Using our ultrastructural assay, it was found that during the 30 min perfusion period neither isoprenaline nor phenylephrine caused a significant change in the rate of secretory granule release, whereas acetylcholine significantly decreased the rate of granule release. A new model of secretion is proposed to integrate these findings with previous results and help clarify the complex picture of atrial natriuretic peptide release.
Newman
T M
TM
National Heart and Lung Institute, Imperial College of Science, Technology, and Medicine, London, United Kingdom.
Severs
N J
NJ
D000109:Acetylcholine / Q000494:pharmacology*; D000316:Adrenergic alpha-Agonists / Q000494:pharmacology*; D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000818:Animals; D009320:Atrial Natriuretic Factor / Q000378:metabolism*; D003594:Cytoplasmic Granules / Q000378:metabolism; D005089:Exocytosis / Q000187:drug effects; D005404:Fixatives; D006325:Heart Atria / Q000378:metabolism*; D047348:Hydrolyzable Tannins; D007545:Isoproterenol / Q000494:pharmacology*; D009206:Myocardium / Q000378:metabolism* / Q000648:ultrastructure; D010656:Phenylephrine / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley
D000316:Adrenergic alpha-Agonists; D000318:Adrenergic beta-Agonists; D005404:Fixatives; D047348:Hydrolyzable Tannins; D010656:Phenylephrine; D009320:Atrial Natriuretic Factor; D007545:Isoproterenol; D000109:Acetylcholine